

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

Brian G. Till,^{1,2} Michael C. Jensen,³ Jinjuan Wang,¹ Eric Y. Chen,¹ Brent L. Wood,⁴ Harvey A. Greisman,⁴ Xiaojun Qian,¹ Scott E. James,¹ Andrew Raubitschek,⁵ Stephen J. Forman,⁶ Ajay K. Gopal,^{1,2} John M. Pagel,^{1,2} Catherine G. Lindgren,² Philip D. Greenberg,^{1,2} Stanley R. Riddell,^{1,2} and Oliver W. Press^{1,2}

¹Clinical Research Division of the Fred Hutchinson Cancer Research Center, Seattle, WA; ²Department of Medicine, University of Washington, Seattle;

³Department of Pediatric Hematology-Oncology, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA; ⁴Department of Laboratory Medicine, University of Washington, Seattle; and ⁵Department of Radioimmunotherapy and ⁶Division of Hematology and HCT, City of Hope National Medical Center and Beckman Research Institute, Duarte, CA

Adoptive immunotherapy with T cells expressing a tumor-specific chimeric T-cell receptor is a promising approach to cancer therapy that has not previously been explored for the treatment of lymphoma in human subjects. We report the results of a proof-of-concept clinical trial in which patients with relapsed or refractory indolent B-cell lymphoma or mantle cell lymphoma were treated with autologous T cells genetically modified by electroporation with a vector plasmid encoding a

CD20-specific chimeric T-cell receptor and neomycin resistance gene. Transfected cells were immunophenotypically similar to CD8⁺ effector cells and showed CD20-specific cytotoxicity in vitro. Seven patients received a total of 20 T-cell infusions, with minimal toxicities. Modified T cells persisted in vivo 1 to 3 weeks in the first 3 patients, who received T cells produced by limiting dilution methods, but persisted 5 to 9 weeks in the next 4 patients who received T cells produced

in bulk cultures followed by 14 days of low-dose subcutaneous interleukin-2 (IL-2) injections. Of the 7 treated patients, 2 maintained a previous complete response, 1 achieved a partial response, and 4 had stable disease. These results show the safety, feasibility, and potential antitumor activity of adoptive T-cell therapy using this approach. This trial was registered at www.clinicaltrials.gov as #NCT00012207. (Blood. 2008;112:2261-2271)

Introduction

Several lymphoma subtypes are incurable with standard chemotherapy and radiation, but immune-based therapies have emerged as effective treatment and offer a potential for cure. Monoclonal antibodies (Abs) against the B-cell lymphoma marker CD20 have activity alone,^{1,2} in combination with chemotherapy,³⁻⁵ or conjugated with radiation-emitting nuclides.⁶⁻⁸ Adoptive cellular therapy with nonmyeloablative allogeneic stem cell transplantation (SCT) or donor lymphocyte infusion (DLI) can eradicate tumors, resulting in long-term survival, even in highly chemotherapy-refractory lymphomas.⁹⁻¹¹ Both of these immunotherapy approaches have limitations, however, because antibodies fail to cure many types of lymphoma, and SCT and DLI, although potentially curative, cannot be used in many patients because of significant toxicity and transplantation-related mortality.

Because the graft-versus-tumor effect of SCT and DLI appears to be mediated by alloreactive donor T lymphocytes,^{12,13} generating T cells specific for tumor antigens minimally expressed in normal tissues is an attractive strategy for harnessing this antitumor effector activity. One technique involves genetically modifying autologous T cells to express a chimeric T-cell receptor (cTCR) that targets a tumor antigen and induces antigen-specific T-cell activation, proliferation, and killing. Because this antigen-induced activation of the T cell occurs in an MHC-independent fashion, a single vector can be used universally to confer recognition of a selected target antigen. By introducing the cTCR into autologous T cells, the

risk of graft-versus-host disease is eliminated. Such genetically modified T cells have been designed to target antigens associated with a variety of tumors, with success in animal models¹⁴⁻¹⁶ and some early evidence of clinical efficacy in human subjects.¹⁷

Our group has developed a technique to manufacture CD20-specific T cells by transfecting peripheral blood mononuclear cells (PBMCs) with a linearized naked DNA plasmid encoding a cTCR derived from a murine anti-human CD20 Ab.¹⁸⁻²⁰ The cell-surface antigen CD20 is an attractive target for immune-based therapies because it is present in more than 90% of B-cell lymphomas, is expressed at a high copy number, is stable on the cell surface, and does not internalize on binding Abs.²¹ These modified T cells secrete interleukin-2 (IL-2) in an antigen-dependent manner,¹⁹ selectively kill CD20⁺ target cells in vitro,²⁰ and eradicate human xenograft tumors in mice.²² Application of this approach to the treatment of lymphoma in human subjects has not yet been described. We report here the results of a proof-of-concept clinical trial in which ex vivo-expanded, genetically modified autologous CD20-specific T cells were used as adoptive cellular therapy for patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL). We show that these T cells can be reproducibly generated and expanded to therapeutic numbers, exhibit in vitro antitumor cytotoxicity, persist in vivo for up to 9 weeks, and appear to be safe, well tolerated, and potentially capable of mediating in vivo antitumor activity.

Submitted December 14, 2007; accepted May 3, 2008. Prepublished online as *Blood* First Edition paper, May 28, 2008; DOI 10.1182/blood-2007-12-128843.

An Inside *Blood* analysis of this article appears at the front of this issue.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2008 by The American Society of Hematology

Methods

Clinical protocol

This clinical protocol was approved by the Fred Hutchinson Cancer Research Center Institutional Review Board, the University of Washington Institutional Biosafety Committee, the US Food and Drug Administration, and the Recombinant DNA Advisory Committee of the National Institutes of Health. Informed consent was obtained in accordance with the Declaration of Helsinki. Patients were eligible if they had a pathologically confirmed diagnosis of CD20⁺ MCL or indolent B-cell lymphoma, had relapsed or refractory disease after at least one prior chemotherapy, were deemed not to be candidates for (or refused) stem cell transplantation, and had serologic evidence of prior Epstein-Barr virus (EBV) exposure (because the TM-LCL cell line used in T-cell culture is EBV-transformed). Patients were excluded if they received fludarabine or cladribine within 2 years before apheresis (but could receive these drugs as cytoreductive therapy after apheresis), anti-CD20 Ab within 4 months of T-cell infusions, or chemotherapy within 4 weeks of T-cell infusions; had lymph nodes more than 5 cm or more than 5000 circulating lymphoma cells in the peripheral blood at the time of T-cell infusions, a previous allogeneic stem cell transplantation, or human anti-mouse Ab (HAMA) seropositivity; required corticosteroids during the study period; had pulmonary or central nervous system involvement with lymphoma; were HIV-seropositive; or were pregnant.

Patients underwent leukapheresis after signing informed consent, and then they were allowed to receive cytoreductive chemotherapy for disease control or debulking during the 2- to 4-month period of T-cell generation, at the discretion of their referring physician. For patients A to E, PBMCs were activated, transfected, and plated at limiting dilution with the intention of isolating and subsequently expanding T-cell clones. This approach proved to be laborious and inefficient, however, and the protocol was modified for patients F to I to allow expansion of modified cells in bulk culture. Patients subsequently received 3 infusions of autologous CD20-specific T cells 2 to 5 days apart in escalating doses (10⁸ cells/m², 10⁹ cells/m², and 3.3 × 10⁹ cells/m²) followed by 14 days of subcutaneous low-dose (500 000 IU/m²) interleukin-2 (IL-2) injections twice daily (patients F-I only). Patients then underwent clinical follow-up to evaluate toxicities related to therapy, which were assessed according to National Institutes of Health Common Terminology Criteria for Adverse Events, version 3.0 (<http://ctep.cancer.gov/>). A Data and Safety Monitoring Board was assembled that performed reviews of the safety data every 6 months. Clinical responses were assessed according to International Working Group criteria.²³

T-cell transfection, selection, and expansion

All cell culture for therapeutic use was performed in the Cell and Gene Therapy Core Laboratory at the University of Washington General Clinical Research Center, under current good manufacturing practice standards. PBMCs collected by apheresis were diluted 1:2 with PBS containing 200 mg/L EDTA, isolated by density gradient centrifugation over Ficoll-Paque (GE Healthcare, Little Chalfont, United Kingdom), washed, and resuspended in RPMI 1640 medium containing 2 mmol of L-glutamine, 25 mmol HEPES, and 10% fetal calf serum. Cells were activated with 30 ng/mL OKT3, and after overnight incubation recombinant human IL-2 was added (50 U/mL).

Electroporation and selection. On day 4 of culture, cells were harvested and resuspended in chilled hypo-osmolar electroporation buffer (Eppendorf North America, New York, NY) at 20 × 10⁶ cells/mL. Cell suspensions were mixed with linearized plasmids (25 μg/mL) encoding a CD20-specific scFvFc:ζ cTCR,^{18-20,24} and divided into aliquots into chilled 0.2-cm electroporation cuvettes. Cells were electroporated with an Eppendorf Multiporator at 250 V for 40 microseconds (μsec) as previously described.²⁰ Approximately 3 days after electroporation, G418 was added to

Generation and expansion of genetically modified T cells. Transfected cells from patients A through E were selected in G418, and attempts were made to generate T-cell clones by limiting dilution as previously described.^{24,25} Although the intention was to isolate clonal populations derived from a single progenitor cell, the plating density required to yield reliable growth of T cells resulted in the presence of 1 to 3 clones per well, as subsequently determined by Vβ TCR spectratyping. For patients F through I, G418-resistant transfected cells were grown in bulk cultures as previously described.²⁵ As cell numbers increased, T cells were transferred to 1-L or 3-L tissue culture bags (Lifecell, Branchburg, NJ). During the expansion, 5 to 8 stimulation cycles were performed. Fresh T cells were infused in patients A and B. For logistic reasons, T cells from patients D, F, G, H, and I were cryopreserved between days 70 and 132 after apheresis in Plasmalyte-A containing 5% HSA and 10% DMSO and thawed 3 to 4 hours before infusion (48 hours before infusion for patient D). Release criteria included detectable cTCR expression by flow cytometry, negative bacterial, fungal, and *Mycoplasma* cultures, endotoxin level no more than 5 EU/kg per hour, Gram stain-negative on day of infusion, greater than 80% cell viability, TCRα/β⁺ and CD3⁺ phenotype by flow cytometry, IL-2 growth dependence, and CD20-specific cytotoxicity.

T-cell clonality assays

T-cell clonality was determined by polymerase chain reaction (PCR) amplification of rearrangements at the T-cell receptor gamma (TCRγ) locus as previously described,²⁶ except that V_γI-J_γ1/2, V_γII-J_γ1/2, V_γI-J_γP1/2, and V_γII-J_γP1/2 rearrangements were amplified in a single multiplex PCR reaction and analyzed by capillary electrophoresis on an Applied Biosystems Model 3130 (Foster City, CA). See Document S1 (available on the *Blood* website; see the Supplemental Materials link at the top of the online article) for detailed methods.

Vβ spectratyping was also performed by flow cytometry. Cells were labeled with monoclonal antibodies CD8 ECD and IOTest Beta Mark Kit (Beckman Coulter, Fullerton, CA). The expression of each of the 24 T-cell receptor isoforms present in the Beta Mark Kit (approximately 70% coverage of the normal human TCR Vβ repertoire) were determined independently on the CD8⁺ T-cell populations, and a threshold of 85% positivity for a single isoform or an absence of expression of all 24 isoforms outside the reference range was considered to represent a clonal expansion. Samples showing 2 or more isoforms outside the reference range were considered oligoclonal.

Western blot assay

Whole cell lysates of modified T cells were probed with a mouse anti-human CD3ζ monoclonal Ab (BD PharMingen, San Diego, CA) as previously described.²⁰

Cytotoxicity assays

T-cell cytotoxicity was analyzed 2 to 7 weeks before planned T-cell infusions to permit selection of optimal "clones" of T cells for expansion. CD20-specific cytotoxicity was assessed with the use of standard chromium-release assays with the following target cell lines: EL4-CD20 (a murine T-cell lymphoma line transfected to express the human CD20 molecule), the parental CD20-nontransfected EL4 cell line, or the Daudi Burkitt lymphoma cell line, as previously described.²⁵ Cytotoxicity assays were repeated in some patients just before T-cell infusions and showed levels of cytotoxicity comparable to assays performed 2 to 7 weeks before infusion.

Flow cytometry for immunophenotypic characterization of T cells and lymphocyte subset analysis

Flow cytometry was performed with the use of standard methods. Briefly, cells cryopreserved within 1 day of the first T-cell infusion were thawed, washed, and labeled with the indicated monoclonal Ab for 15 minutes at room temperature in the dark. The samples were then washed once, resuspended in a dilute DNA binding dye (DAPI), incubated for 10 minutes,

developed in our laboratory (WoodList). Positivity for DAPI was used to exclude nonviable cells, and thresholds for positivity were determined with unstained cells and isotype control Ab, as appropriate. Antibodies were used at the manufacturer's recommended concentrations. A complete list of Abs used is included in Document S1. Flow cytometry to detect cTCR expression was performed using a FITC-labeled polyclonal goat anti-mouse IgG Fab-specific Ab (Sigma-Aldrich, St Louis, MO) as previously described.²⁵

Detection of modified T cells in vivo

PBMCs collected serially after T-cell infusions were isolated by Ficoll density-gradient centrifugation, and genomic DNA was extracted using a QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA). The standard consisted of 10-fold serial dilutions of purified scFvFc:ζ plasmid DNA starting at 10^6 copies/μL, with each sample containing 1 μg of preinfusion PBMC DNA to control for background signal. The negative control was preinfusion PBMC genomic DNA. A 72-bp (base pair) fragment containing portions of the CD3ζ chain and adjacent CD4 transmembrane domain sequences was amplified using forward primer 5'-TCGCCGGCCTCCTGCTT-3' and reverse primer 5'-CGTCTGCGCTCCT-GCTGA-3'. The probe used was 5'-FAM-TGGGCTAGGCATCTTCTTCA-GAGTGAA-TAMRA-3'. Primers that amplify a fragment of the β-actin gene (TaqMan B-actin Detection Reagent Kit; Applied Biosystems) were used as an internal control and for normalization of DNA quantities. Quantitative real-time PCR was performed in triplicate with 1 μg DNA in each reaction, using TaqMan Universal PCR Master Mix in a 7900HT Sequence Detection System (all Applied Biosystems).

Immune response assays

Two assays were performed to test for humoral immune responses to the cTCR. In the first assay, 96-well enzyme-linked immunosorbent assay (ELISA) plates were coated with 0.5 μg Leu-16 murine anti-human CD20 Ab (BD Biosciences, San Diego, CA) in pH 9.6 carbonate buffer and blocked with 5% milk before adding samples of goat anti-mouse IgG Fab-specific Ab (standard curve; Jackson ImmunoResearch Laboratories, West Grove, PA), serially diluted 2% BSA/PBS (negative control), baseline patient serum (negative control), HAMA⁺ patient serum (positive control), or study subject serum from serial postinfusion time points. Biotinylated Leu-16 murine anti-human CD20 Ab (BD Biosciences; 10 μg/mL) was added to each well as the primary Ab, followed by 1:1000 horseradish peroxidase-Avidin D (BD Biosciences). Samples were incubated for 30 minutes at room temperature and washed 3 times with 0.01 M PBS/0.3% Tween between each step. Color reagent (2,2'-azino-bis[3-ethylbenzothiazoline-6-sulfonic acid] diammonium salt; Sigma-Aldrich) at 0.42 mg/mL in citrate buffer (citrate 10.5 mg/mL, pH 4.0) plus hydrogen peroxide (100 μL/12 mL buffer) was added to each well; absorbency was read with a Bio-Tek XS ELISA reader (Bio-Tek Instruments, Winooski, VT). Optical density measurements were converted to concentration values as calculated from the standard curve. In the second assay, flow cytometry was used to assess the presence of anti-cTCR Ab in posttreatment patient serum samples (see Document S1 for detailed methods).

Cellular immune response assays were performed by cocultivating patient-derived PBMCs (10^6 cells/mL) serially collected after T-cell infusions with irradiated anti-CD20 cTCR-expressing T cells (10^6 cells/mL) from infused batches, at a 2:1 ratio. After 2 rounds of stimulation 1 week apart, the PBMCs were tested in ⁵¹Cr release cytotoxicity assays using either autologous T cells transfected with the cTCR-encoding plasmid or nontransfected autologous PBMC as target cells at a 25:1 E/T ratio. In the first 2 patients treated we also assessed the responsiveness of recovered T cells to histocompatibility locus antigen-disparate cells as a positive control.

Results

Study design and patient characteristics




Figure 1. Schema of clinical protocol.

T cells bearing a CD20-specific cTCR to treat indolent and mantle cell lymphomas. Autologous PBMCs were collected by apheresis, genetically modified, and expanded ex vivo, a process that typically required 2 to 4 months. During this interval patients underwent cytoreductive chemotherapy if necessary for tumor debulking or to maintain disease control. Subjects were then treated with 3 infusions of modified CD20-specific T cells, 2 to 5 days apart, at incremental doses (10^8 cells/m², 10^9 cells/m², and 3.3×10^9 cells/m²) similar to those used in previous adoptive T-cell therapy trials,²⁷ but with a shorter interval between infusions to limit the potential for development of an immune response against the transfected cells. The last 4 patients received low-dose subcutaneous injections of IL-2 twice daily for 14 days after the final T-cell infusion to enhance in vivo T-cell survival and proliferation. Patients then underwent follow-up for clinical and research end points, and long-term monitoring for adverse events for 2 years. The study design is outlined in Figure 1.

Nine patients with relapsed or refractory indolent B-cell NHL or MCL were enrolled: 8 men and 1 woman between the ages of 43 and 77 years; 8 had relapsed follicular lymphoma, and 1 had relapsed MCL. Patients had been treated with a median of 2 prior therapies (range, 1-7 therapies; Table 1).

Generation and expansion of autologous CD20-specific T cells

PBMCs collected by apheresis were stimulated with anti-CD3 Ab (OKT3) and IL-2 and transfected by electroporation with a naked DNA plasmid encoding a cTCR consisting of a murine kappa leader sequence, CD20-specific scFv derived from the Leu16 murine Ab, human IgG1 C_H2C_H3 hinge, human CD4 transmembrane, and human CD3ζ intracellular signaling domain, as well as a neomycin resistance gene (neoR) under a separate promoter (Figure 2A).^{20,25} Anti-CD20 cTCR surface

Table 1. Patient characteristics

Patient	Age, y	Sex	Diagnosis	Stage	Prior therapies	Cytoreductive therapy before T-cell infusions
A	44	F	FL	IV-B	R-CHOP	CVP
B	70	M	FL	II-A	CHOP, rituximab, ¹³¹ I-tositumomab	CVP
C	47	M	FL	IV-B	ProMACE/MOPP, ASCT, fludarabine (10 cycles)	CVP
D	60	M	FL	IV-A	Rituximab	CVP
E	63	M	MCL	IV-A	R-HyperCVAD, GCD-R	None
F	46	M	FL	IV-A	R-CVP	FND
G	43	M	FL	IV-A	CHOP, IFN, CY + VP16, R-CY, CY + DEX, GCD-R, ASCT	None
H	46	M	FL	IV-B	R-CHOP, fenretinide	FND
I	77	M	FL	III-A	R-CVP, R-CHOP, GCD-R	¹³¹ I-tositumomab

F indicates female; M, male; FL, follicular lymphoma; MCL, mantle cell lymphoma; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R, rituximab; CVP, cyclophosphamide, vincristine, and prednisone; ProMACE/MOPP, procarbazine, methotrexate with leucovorin, doxorubicin, cyclophosphamide, etoposide, mechlorethamine, vincristine, and prednisone; ASCT, high-dose therapy followed by autologous stem cell transplantation; HyperCVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with cycles of high-dose cytarabine and methotrexate; GCD, gemcitabine, carboplatin, and dexamethasone; FND, fludarabine, mitoxantrone, and dexamethasone; IFN, interferon- α ; CY, cyclophosphamide; VP16, etoposide; and DEX, dexamethasone.

Modified T cells were generated for the first 5 patients by limiting dilution and selected for CD20 cytotoxicity by chromium release assay and cTCR expression by flow cytometry. At the plating density required to reproducibly generate modified T cells, the resulting T-cell populations consisted of cells derived from 1 to 3 clones of T cells as assessed by V β TCR spectratyping and TCR γ clonality testing by PCR (Figure 3A; Table S1). This expansion and selection process proved to be laborious and inefficient, requiring approximately 4 months to achieve the target cell dose. Moreover, T cells generated by limiting dilution could not be expanded adequately for infusions in 2 of these initial 5 patients, and in 2 of the other 3 patients the target cell doses could not be reached (Table 2).

We subsequently elected to modify the protocol to include expansion of T-cell transfectants in bulk culture to circumvent the difficulties of expanding T cells after limiting dilution. Successful expansion of modified T cells was achieved for the subsequent 4 patients using this approach, and the time required to reach the target cell dose was reduced by approximately 50% (Figure 4). V β TCR spectratyping and TCR γ clonality testing by PCR showed more heterogeneous T-cell populations in these bulk cultures, although several of the cultures contained prominent T-cell clones

(Figure 3B; Table S1). Three of these 4 patients received all planned doses of T cells. The target cell number was reached for the fourth patient as well, but the third infusion consisted of only 2×10^9 cells/m² because of a loss of cells during a quality control assay.

Immunophenotype of modified T cells

The phenotype of ex vivo-expanded cTCR-bearing T cells has not been well described. We analyzed the immunophenotype of the infused T cells using multicolor flow cytometry and found it to be similar to that of activated effector T cells,^{28,29} expressing CD3, CD8, and CD45RO and lacking CD62L, CCR7, and CD127 (Figure 5). As expected, patients treated with CD8⁺ T cells derived by limiting dilution received negligible numbers of CD4-expressing cells (0.67%-4.5%), whereas patients receiving infusions of T cells grown in bulk culture received 3.4% to 38.6% CD4⁺ cells. Infused T cells also expressed the activation marker CD95, but relatively few cells (1.3%-6.2%) expressed CD134 (OX40; Table 3). We found negligible numbers of cells expressing central memory (CD62L⁺/CCR7⁺/CD45RA⁻/CD127⁺) and effector memory (CD62L⁻/CCR7⁻/CD45RA⁻/CD127⁺) phenotypes.




Figure 2. Expression of the CD20-specific cTCR. (A) Schematic diagram of the CD20-specific scFvFc:ζ chimeric T-cell receptor cDNA plasmid. (B) A representative Western blot analysis of cTCR expression performed using whole-cell lysates of preinfusion T cells from patient B, probed with mouse anti-human CD3 ζ monoclonal Ab. Negative




Figure 3. Clonality of T cells produced by limiting dilution and in bulk culture. T-cell clonality was determined by flow cytometric T-cell receptor (TCR) Vβ spectratyping (top) and by PCR amplification of clonal V-J rearrangements at the TCRγ locus (bottom). Representative results for T cells produced by limiting dilution (A) and in bulk culture (B) are shown. (A) T cells produced by limiting dilution (patient B), showing clonal expression of Vβ17 in 98% of CD8⁺ T cells by Vβ spectratyping (top; ■) and showing 2 predominant TCRγ rearrangements (bottom). Because each T-cell clone can rearrange one or both of its TCRγ alleles, the 2 PCR products could represent either 1 T-cell clone with biallelic TCRγ rearrangements or 2 singly rearranged clones, although the single predominant Vβ17 clone identified by spectratyping would favor a single doubly rearranged clone. (B) T cells produced in bulk culture (patient G) showing oligoclonal Vβ expression in CD8⁺ T cells (16% Vβ16; 9% Vβ7.1; 3% each Vβ3, Vβ13.2 and Vβ17; 2% each Vβ1 and Vβ13.1; and 1% each Vβ5.1, Vβ13.6, Vβ21.3, and Vβ23) and 7 distinct TCRγ rearrangements by PCR (bottom; ■) that could correspond to between 4 and 7 different T-cell clones, depending on the number of singly and doubly rearranged clones (see Table S1). The □ in both top panels represent the average expression levels for each Vβ chain in normal polyclonal T-cell populations.

T cells resulting from bulk culture and from limiting dilution were phenotypically similar, although the former generally contained higher proportions of CD4⁺ cells (3.4%-38.6% compared with 0.67%-4.5%) and cells with a regulatory T (Treg)-like phenotype (CD4⁺/CD25⁺/FoxP3⁺) (0.54%-1.9% compared with 0.61%-21.6%). Treg functionality studies were not performed, however. All T cells exhibited low expression of costimulatory markers CD28 (0.92%-5.4%) and CD137 (0.47%-4.4%). High proportions of cells from all patients expressed adhesion molecules such as CD11a (98.7%-100%), CD44 (99.8%-100%), and CD49d (85.8%-99.6%).

Cytotoxicity of modified T cells in vitro

Our group showed in preclinical studies that T-cell clones bearing CD20-specific cTCRs exhibit antigen-specific cytotoxicity.²⁰ We assessed the cytotoxicity of T cells used in this trial by coinubation with ⁵¹Cr-labeled CD20⁺ target cells (Daudi lymphoma cells and EL4 mouse lymphoma cells transfected to express human CD20), and the expanded T cells used for all 7 patients killed CD20⁺ lymphoma cells in an antigen-specific manner (Figure 6).

Table 2. T-cell infusions

Patient	Infusion 1, cells/m ² *	Infusion 2, cells/m ² †	Infusion 3, cells/m ² ‡	Fresh versus thawed cells	Time from apheresis to target cell number, d	No. of stimulation cycles§
A	10 ⁸	10 ⁹	3.3 × 10 ⁹	Fresh	130	7
B	10 ⁸	10 ⁹	2 × 10 ⁹	Fresh	129+	7
C					Expansion failed	5
D	10 ⁸	4 × 10 ⁸		Thawed	159+	7
E					Expansion failed	5
F	10 ⁸	10 ⁹	3.3 × 10 ⁹	Thawed	96	6
G	10 ⁸	10 ⁹	3.3 × 10 ⁹	Thawed	90	5
H	10 ⁸	10 ⁹	3.3 × 10 ⁹	Thawed	81	5
I	10 ⁸	10 ⁹	2 × 10 ⁹	Thawed	104	8

For patients A through E, T cells were selected and expanded by limiting dilution. For patients F through I, T cells were expanded in bulk culture. Patients C and E did not receive T-cell infusions. Patients B and D received infusions but did not reach the target cell dose.

*Target dose was 10⁸ cells/m².
 †Target dose was 10⁹ cells/m².
 ‡Target dose was 3.3 × 10⁹ cells/m².

Downloaded from http://ashpublications.org/blood/article-pdf/112/6/2261/1482893/zh1801.808002261.pdf by guest on 31 May 2022

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.